ABSTRACT
OBJECTIVES: We sought to characterize the evolution, during maturational growth and early ageing, of the messenger abundance of four genes involved in cardiac fibrosis regulation (procollagens alpha2(I) and alpha1(III), transforming growth factors beta1, and beta3) and corroborate it with the alterations in collagen deposition in cardiac interstitium and around coronary arteries. METHODS: Messenger RNA was quantified in LV and RV of 2-, 6-, 12- and 19-month-old male Sprague-Dawley rats (n = 5 per group) with Northern blot analysis. Collagen deposition was quantified with a semi-automated image analyser on Sirius red-stained sections of LV tissue. RESULTS: There was an age-related monotonous decrease of procollagen type I (COL-I) transcript abundance in LV (p < 0.001) but not in RV. Procollagen type III (COL-III) expression decreased rapidly during maturational growth, both in LV and RV. On the other hand, collagen deposition in myocardial interstitium and around coronary arteries was slightly augmented during the maturational period of life (2-12 months), but with a higher rate during early ageing (up to 19 months). This was not accompanied by a significant thickening of the wall of coronary arteries. Transforming growth factor beta1, (TGF-beta1) and transforming growth factor beta3 (TGF-beta3) transcript abundance showed no major variations during ageing. CONCLUSIONS: These results reflect a striking ventricular difference regarding the age-dependent expression of COL-I. The expression of TGF-beta(s), pleiotropic factors known to influence collagen pathway at different levels, does not seem to be profoundly altered during ageing. The discrepancy between protein and COL-I and COL-III mRNA levels indicates differences in age-related mRNA stability and/or regulation of collagen translation.
Subject(s)
Aging/metabolism , Collagen/metabolism , Endomyocardial Fibrosis/metabolism , Myocardium/metabolism , Procollagen/genetics , Transforming Growth Factor beta/genetics , Animals , Arteries/metabolism , Arteries/pathology , Body Mass Index , Coronary Vessels/metabolism , Coronary Vessels/pathology , Endomyocardial Fibrosis/genetics , Gene Expression , Heart/physiology , Male , Organ Size , Rats , Rats, Sprague-DawleyABSTRACT
The incidence of heart failure in the population increases steeply among older people. Overactivation of the sympathetic nervous system is associated to and responsible for worsening of heart failure. This study describes the influence of aging on short-term left ventricular (LV) adaptation to b-adrenergic stimulation in Wistar rats. In controls at 18 mo, interstitial fibrosis was increased with respect to 3-mo-old rats, whereas myocytes dimension and the messenger RNA (mRNA) abundance of atrial natriuretic peptide (ANP), a2(I) procollagen, transforming growth factor (TGF-b1, TGF-b3), and secreted protein, acidic and rich in cysteine (SPARC) were not different. To determine how aging affects LV adaptation to adrenergic stimulation, two groups of animals received isoproterenol (ISO, 1 mg/kg/d) for 3 days. There was no significant difference between young and older rats with respect to increase in LV weight, myocytes dimension, and mRNA abundance of all the genes considered, except a1(III) procollagen. These findings indicate that despite limited compensatory hypertrophy and higher fibrosis, LV from aged nonsenescent rats preserves the capacity to adapt to b-adrenergic stimulation through the upregulation of several genes encoding extracellular matrix-related proteins.
Subject(s)
Adaptation, Physiological , Adrenergic beta-Agonists/pharmacology , Aging/physiology , Isoproterenol/pharmacology , Ventricular Function, Left/drug effects , Analysis of Variance , Animals , Atrial Natriuretic Factor/metabolism , Blotting, Northern , Cardiomegaly , Collagen/metabolism , Gene Expression Regulation/drug effects , Heart Rate/drug effects , Male , Myocardium/metabolism , Rats , Rats, Wistar , Transforming Growth Factor beta/metabolism , Up-Regulation , Ventricular Function, Left/geneticsABSTRACT
Because progressive fibrosis is a histological hallmark of the aging kidney, we sought to characterize the course of some fibrosis-related genes [pro-alpha2(I)collagen (COL-I), pro-alpha1(III)collagen (COL-III), and transforming growth factors beta1 and beta3 (TGF-beta1 and TGF-beta3)] of interstitial collagen accumulation [COL-I and COL-III proteins, hydroxyproline (PRO-OH), histology] and its degradation (matrix metalloproteinase MMP-1 and -2) during maturation and early aging in rats. During the lifespan considered we observed no changes in the mRNA, except that COL-I mRNA tended to be up-regulated from 2 to 19 months of age. However, progressive fibrosis was histologically detectable, with COL-I accumulation (p < .05 and p < .01 in 12-month- and 19-month-old rats vs the youngest), and confirmed by the PRO-OH tissue levels (p = .0001); COL-III seemed to be less involved. The MMP-1 protein level decreased significantly in the cortex of 12-month- and 19-month-old rats (p < .05), whereas MMP-2 protein level and activity remained essentially unchanged. These results show that, during aging of the kidney, (i) renal cortex fibrosis is explained by COL-I accumulation as a consequence of an altered balance between its synthesis and degradation, and (ii) the expression of the pleiotropic factor TGF-beta in the renal cortex is not modified.
Subject(s)
Collagen/biosynthesis , Collagen/genetics , Kidney Cortex/metabolism , Kidney Cortex/pathology , Transforming Growth Factor beta/biosynthesis , Transforming Growth Factor beta/genetics , Age Factors , Animals , Fibrosis , Gene Expression , Hydroxyproline/metabolism , Kidney Cortex/enzymology , Male , Matrix Metalloproteinase 1/metabolism , Matrix Metalloproteinase 2/metabolism , RNA, Messenger/biosynthesis , Rats , Rats, Sprague-DawleySubject(s)
Adjuvants, Immunologic/pharmacology , Aging/immunology , Escherichia coli Infections/immunology , Gene Expression Regulation/drug effects , Interleukin-2/biosynthesis , Pyrrolidonecarboxylic Acid/analogs & derivatives , RNA, Messenger/biosynthesis , Shock, Septic/immunology , Spleen/chemistry , Thiazoles/pharmacology , Tumor Necrosis Factor-alpha/biosynthesis , Aging/genetics , Aging/metabolism , Animals , Escherichia coli Infections/metabolism , Interleukin-2/genetics , Male , Pyrrolidonecarboxylic Acid/pharmacology , Rats , Rats, Sprague-Dawley , Shock, Septic/metabolism , Spleen/drug effects , Spleen/pathology , Stimulation, Chemical , Thiazolidines , Tumor Necrosis Factor-alpha/geneticsSubject(s)
Influenza Vaccines/administration & dosage , Influenza, Human/prevention & control , Adult , Aged , Antibodies, Viral/immunology , Female , Humans , Influenza Vaccines/immunology , Influenza, Human/epidemiology , Influenza, Human/immunology , Italy/epidemiology , Male , Middle Aged , SeasonsABSTRACT
The protective activity of pyridoxol L,2-pyrrolidon-5 carboxylate (metadoxine) was investigated in a rat model of carbon tetrachloride (CCL4)-induced hepatic fibrosis. After 6 weeks of CCl4 treatment, the animals developed fibrosis and inflammation of the liver while those treated with CCl4 + metadoxine had less severe lesions (P < 0.05). Since in liver fibroplasia there are quantitative changes of the extracellular matrix components and almost invariably a decrease in albumin synthesis, we have also investigated by Northern blot analysis the expression of the cellular fibronectin, pro-alpha 2(I)collagen and albumin genes. There were striking increases in fibronectin and pro-alpha 2(I)collagen mRNA contents in the livers of CCL4-treated animals and these enhancements were less evident in the metadoxine-treated rats. In contrast, albumin mRNA levels, almost identical in control and metadoxine-treated rats, were lower in the CCl4-treated animals. These data suggest that metadoxine might slow the development of CCl4-mediated liver fibrosis.
Subject(s)
Albumins/genetics , Fibronectins/genetics , Gene Expression Regulation/drug effects , Liver Cirrhosis, Experimental/metabolism , Procollagen/genetics , Pyridoxine/pharmacology , Pyrrolidonecarboxylic Acid/pharmacology , Albumins/drug effects , Animals , Blotting, Northern , Carbon Tetrachloride , Disease Models, Animal , Drug Combinations , Female , Fibronectins/drug effects , Liver Cirrhosis, Experimental/chemically induced , Liver Cirrhosis, Experimental/pathology , Procollagen/drug effects , RNA/analysis , Rats , Rats, Sprague-DawleyABSTRACT
Common features of chronic alcoholic liver disease are progressive hypoalbuminemia and liver fibrosis. The molecular mechanisms which account for these effects are still controversial. Therefore, in the present study we evaluated albumin and collagen gene expression in livers of alcohol abusers and patients with viral-induced liver disease. Albumin and pro-alpha 1 (I) collagen mRNA levels were determined in 30 patients who underwent diagnostic liver biopsy. Of 14 alcoholics, 7 had alcoholic hepatitis alone, while the other 7 had cirrhosis plus alcoholic hepatitis. Of 16 non-alcoholic patients with chronic viral infection, 6 had chronic active hepatitis and 10 cirrhosis plus chronic active hepatitis. Total RNA was extracted from a portion of each biopsy, hybridized with a human albumin or collagen cDNA clone and compared to 2 normal surgical specimens which served as controls. The Northern hybridization studies revealed that: despite the presence of inflammation and fibrosis, the albumin mRNA levels of alcoholics were similar to normal controls; these alcoholics had significantly higher levels of albumin mRNA than did patients with similar histological stages of disease due to viral infection; and all the categories of patients had markedly increased procollagen mRNA levels when compared to controls. Given these results it is tempting to speculate that alcohol may actually increase albumin mRNA content in man as it does in animals. Furthermore, the increased procollagen mRNA levels in fibrotic livers suggest that an increase in collagen synthesis may be a significant factor in the pathogenesis of hepatic fibrosis.
Subject(s)
Albumins/genetics , Gene Expression Regulation , Hepatitis, Chronic/genetics , Liver Diseases, Alcoholic/genetics , Procollagen/genetics , Albumins/biosynthesis , Biopsy , Female , Hepatitis B/genetics , Hepatitis B/metabolism , Hepatitis B/pathology , Hepatitis C/genetics , Hepatitis C/metabolism , Hepatitis C/pathology , Hepatitis, Alcoholic/genetics , Hepatitis, Alcoholic/metabolism , Hepatitis, Alcoholic/pathology , Hepatitis, Chronic/metabolism , Hepatitis, Chronic/pathology , Humans , Liver Cirrhosis, Alcoholic/genetics , Liver Cirrhosis, Alcoholic/metabolism , Liver Cirrhosis, Alcoholic/pathology , Liver Diseases, Alcoholic/metabolism , Liver Diseases, Alcoholic/pathology , Male , Procollagen/biosynthesis , RNA, Messenger/biosynthesis , RNA, Messenger/geneticsABSTRACT
We explored the protective activity of glutathione (GSH) in a rat model of carbon tetrachloride-induced acute liver damage. Histological examination of livers from GSH-pretreated rats revealed minor damage, confirmed by biochemical parameters of liver cell necrosis evaluated both 24 and 48 hr after hepatotoxin delivery. In addition we quantified changes in hepatic steady-state levels of albumin, type I procollagen, transforming growth factor-beta 1 and tumour necrosis factor-alpha mRNAs. Even at the molecular level and above all for the albumin gene, it appears that GSH lessens the effect of the hepatotoxin, however the protection of the thiol is restricted to the first 24 hrs and is almost totally exhausted after 48 hr. Since, only 24 hr after CC14 delivery, GSH abundance determined in erythrocytes and liver is almost equal in the controls and in the GSH injected rats, but significantly higher than in the only intoxicated animals (P < 0.05, intraerythrocyte content), we conclude that the thiol pretreatment exerts an effective but transient protection.
Subject(s)
Carbon Tetrachloride/toxicity , Glutathione/administration & dosage , Liver/drug effects , Animals , Biomarkers/blood , Blotting, Northern , Erythrocytes/metabolism , Glutathione/analysis , Liver/metabolism , Liver/pathology , Male , Necrosis , Procollagen/blood , Procollagen/genetics , RNA, Messenger/analysis , Rats , Rats, Sprague-Dawley , Serum Albumin/genetics , Serum Albumin/metabolism , Transforming Growth Factor beta/blood , Transforming Growth Factor beta/genetics , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolismABSTRACT
Older individuals are more susceptible to infectious agents than younger and this is related to the disrepair of the immune defence mechanisms associated with aging. In this study we evaluated the activity of a new biological response modifier (BRM), pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl)carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) in relation to the expression of some cytokine genes. We utilized 24 month-old Sprague-Dawley rats (n = 24), randomly divided into 4 groups: controls (n = 6), pidotimod-treated (n = 6; 200 mg/kg i.p., for 10 days), infected (n = 6; i.p. infection of E. coli CH 198) and pidotimod-treated + infected (n = 6). Poly(A+)RNA purified from the spleens of the animals killed 48 h after the infection was probed with Interleukin-2 (IL-2) and Tumor Necrosis Factor-alpha (TNF-alpha) cDNA clones. Northern blot analysis showed a slight signal of the IL-2 steady state mRNA in the groups of control, pidotimod-treated and infected animals, with an increase (20%) evident only in pidotimod + infected rats, 48 h after E. coli injection. On the contrary, the TNF-alpha mRNA levels were easily detectable in controls and infected rats and lower (20%, 40%) following the drug treatment, independent of i.p. infection. These results account for the BRM activity of pidotimod.
Subject(s)
Gene Expression Regulation/drug effects , Immunologic Factors/pharmacology , Interleukin-2/biosynthesis , Pyrrolidonecarboxylic Acid/analogs & derivatives , Shock, Septic/immunology , Spleen/metabolism , Thiazoles/pharmacology , Tumor Necrosis Factor-alpha/biosynthesis , Aging/immunology , Animals , Blotting, Northern , Interleukin-2/genetics , Male , Pyrrolidonecarboxylic Acid/pharmacology , RNA/biosynthesis , RNA/isolation & purification , Rats , Rats, Sprague-Dawley , Spleen/drug effects , Thiazolidines , Tumor Necrosis Factor-alpha/geneticsABSTRACT
Our objectives were (i) to evaluate the expression of several genes involved in the remodelling of cardiac extracellular matrix (ECM), with a special interest on SPARC (secreted protein acidic and rich in cysteine) a glycoprotein with anti-adhesive properties, and (ii) to characterise structural changes in the left (LV) and right (RV) ventricles of rats subjected to continuous beta-adrenergic stimulation. The rats were infused for 3 or 7 days with isoproterenol (ISO, 4 mg/kg/day) or vehicle. Hybridisation analysis was done for SPARC, atrial natriuretic peptide (ANP),alpha2 (I) [COL-I] and alpha1 (III) [COL-III] procollagens, TGF-beta1 and TGF-beta3 mRNA content. Interstitial and perivascular collagen deposition in both ventricles was measured after specific staining. The mean cross-sectional area of LV cardiomyocytes was evaluated by quantitative histomorphometry. ISO provoked an increase of LV mass, and a progressive enlargement of cardiomyocytes: their cross-sectional area raised from 205+/-8 micrometer2 in vehicle-treated animals to 247+/-4 and 296+/-9 micrometer2 after 3 or 7 days of ISO infusion, respectively (P<0.001). SPARC messenger abundance increased by more than 50% in LV and RV, a first evidence of its expression in the myocardium of adult rats. Transcripts of ANP, COL-III, TGF-beta1 and TGF-beta3 increased in both ventricles. COL-I transcript increased in LV (75 and 116% on days 3 and 7), but not in RV. In LV, collagen accumulated in the interstitium (2.69+/-0.20v 9. 23+/-0.50% of tissue area for vehicle and ISO 7 days groups, P<0.05) and around coronary arteries (1.04+/-0.11v 4.47+/-0.48% of lumen area for vehicle and ISO 7 days,P<0.05). Cardiac fibrosis was less marked in RV. In conclusion, early expression of SPARC, an anti-adhesive protein, and preferential expression of COL-III, a distensible form of collagen, should increase ECM plasticity and facilitate ventricular remodelling.
Subject(s)
Adrenergic beta-Agonists/pharmacology , Extracellular Matrix/metabolism , Heart/drug effects , Myocardium/metabolism , Osteonectin/metabolism , Animals , Atrial Natriuretic Factor/drug effects , Atrial Natriuretic Factor/genetics , Cardiomegaly , Collagen/drug effects , Collagen/metabolism , Extracellular Matrix/drug effects , Fibrosis , Gene Expression Regulation/drug effects , Heart Ventricles/drug effects , Heart Ventricles/metabolism , Isoproterenol/pharmacology , Male , Myocardium/pathology , Osteonectin/drug effects , Rats , Rats, Wistar , Transforming Growth Factor beta/drug effects , Transforming Growth Factor beta/genetics , Up-RegulationABSTRACT
Little is known about the distribution of IgG-bearing cell subpopulations in normal liver and their possible changes in disease conditions. We developed an immunohistochemical method that proved suitable and accurate for the identification and characterization of IgG-bearing cells and their subpopulations in liver specimens. The method uses specific monoclonal antibodies on serial mirror liver sections. We applied this method to four normal liver tissue specimens and 25 liver biopsy samples of chronic hepatitis of viral etiology. Only rare IgG-bearing cells could be observed in the portal tracts of normal liver specimens. In contrast, a dense infiltrate of such cells was seen in liver specimens from patients with chronic viral hepatitis. The density of IgG-bearing cells in such patients ranged from 6 to 20 cells x 10(-4) micron2 in the different specimens (mean = 11 x 10(-4) micron2). The increase in IgG-bearing cells did not appear to be related to the histological diagnosis, to the degree of histological inflammatory activity or to the type of viral infection. The major population of IgG-bearing cells consisted of IgG1-positive cells (68%); IgG2- (17%), IgG3- (8%) and IgG4 (7%)-bearing cells represented only minor fractions. The increased prevalence of IgG1-bearing cells observed in chronic hepatitis but not in normal liver specimens suggests that these findings may reflect an activation of antibody production directed toward viral antigens or antigenic structures of self. The identification of the antigenic specificities of the antibodies produced by IgG-bearing cells might provide important clues in understanding the pathogenesis of chronic viral hepatitis.
Subject(s)
Hepatitis, Viral, Human/immunology , Immunoglobulin G/metabolism , Liver/immunology , Portal System/immunology , Biopsy, Needle , Computers , Hepatitis B Surface Antigens/analysis , Hepatitis, Viral, Human/pathology , Humans , Immunoenzyme Techniques , Immunoglobulin G/analysis , Immunoglobulin G/classification , Liver/pathology , Portal System/pathology , Reference ValuesABSTRACT
We compared the effects of an ACE inhibitor, captopril, with those of a DA2-dopaminergic/alpha2-adrenergic receptor agonist (CHF-1024) on neuroendocrine activation and cardiac fibrosis in a model of pressure-overload hypertrophy. Interrenal aortic stenosis was performed in 89 rats, treated with CHF-1024 (0.33, 2 or 6 mg kg(-1) day(-1)), or captopril (1 g/L). Hemodynamic variables were recorded. Cardiac and renal weights, plasma aldosterone, renin activity and urinary catecholamine excretion were measured, as well as cardiac collagen. Blood pressure was lower in stenotic animals treated with CHF-1024 compared to vehicle (161 +/- 10 vs 219 +/- 10 mmHg, p < 0.01), but LV weight was similar. CHF-1024 elicited a marked dose-dependent attenuation of urinary norepinephrine excretion (1.80 +/- 0.18 in controls compared to 0.40 +/- 0.14 microg/24 h at the highest dose, p < 0.01) and of LV perivascular fibrosis. Captopril provoked a marked hypotension, reduced cardiac and body weights, plasma aldosterone concentration, dopamine excretion and perivascular collagen. The DA2/alpha2 agonist CHF-1024 effectively blunts adrenergic drive and cardiac fibrosis in a rat model of pressure overload.